{
    "medicine_id": "b816602e210ad880294e6e0df12182fa5eaf523d",
    "platform_id": "DB11607",
    "metadata": {
        "name": "Eloctate 250 iU 3mL Kit",
        "composition": "250 iU 3mL Efmoroctocog alfa",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A congenital factor VIII deficiency FDA Label",
            "contraindications": {
                "disease": "Based on the findings from acute and repeated dose toxicity studies efmoroctocog alfa displays no special hazard for humans Studies to assess the genotoxicity carcinogenicity toxicity to reproduction or embryo foetal development of efmoroctocog alfa have not been conducted In a placental transfer study efmoroctocog alfa has been shown to cross the placenta in small amounts in mice FDA Label",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "In two multinational open label noncomparative phase III trials involving previously treated pediatric and adult patients with severe haemophilia A the clinical efficacy and safety of efmoroctocog alfa have been studied The bleeding episodes were adequately controlled and bleeding rates were substantially reduced when efmoroctocog alfa has been used for individualized prophylaxis or treatment of bleeding FDA Label In adult patients receiving a single preoperative dose to maintain haemostasis during surgical procedures the total dose on the day of surgery needed to maintain haemostasis ranged from 50 8 to 126 6 IU kg FDA Label",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}